Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Colorado Vaccination Site Temporarily Closed After Some People Experience Adverse Reactions

04/08/2021 | 11:50am EDT

By Talal Ansari

A mass-vaccination site in Colorado was closed Wednesday after some people experienced adverse effects after being given a shot of the Johnson & Johnson Covid-19 vaccine.

A total of 11 patients were affected, according to Centura Health, one of the largest healthcare networks in the region, which runs the site along with the state of Colorado.

"Medical staff on site determined two individuals required additional observation and out of an abundance of caution, they were transported to a nearby hospital," Centura Health said in a statement.

It is unclear whether the adverse reactions were related to the vaccine.

Johnson & Johnson didn't immediately comment. The Colorado Department of Public Health and Environment didn't immediately respond to a request for comment.

The vaccination site at Dick's Sporting Goods Park, a stadium in Commerce City, just outside of Denver, was closed for the remainder of the day and existing appointments were rescheduled. The site is normally closed from Thursday to Saturday. Normal operations will resume on Sunday, a Centura Health spokesperson said.

More than 1,700 individuals had received vaccinations Wednesday, Centura Health said. The patients who experienced adverse reactions accounted for 0.62% of those vaccinated, it said.

Federal health regulators authorized](https://www.wsj.com/articles/j-j-covid-19-vaccine-authorized-for-use-in-u-s-11614467922?mod=article_inline) Johnson & Johnson's [one-shot vaccine (https://www.wsj.com/articles/j-js-covid-19-vaccine-how-effective-is-it-and-when-will-it-be-available-11611940438) in late February, saying it was safe and effective. It is one of three vaccines authorized for use in the U.S., along with those from Pfizer and partner BioNTech, and Moderna.

Early safety monitoring of Covid-19 vaccines has found rare reports (https://www.wsj.com/livecoverage/covid-2021-01-27/card/rp3ap8cztv3WkYSLBcq6) of severe allergic reactions after vaccination, according to the Centers for Disease Control and Prevention.

The Food and Drug Administration says people who are allergic to the ingredients of a vaccine shouldn't take it. The vaccines from Pfizer and Moderna contain, among other ingredients, the genetic material RNA and a substance called polyethylene glycol, which has been associated with rare allergic reactions. The J&J vaccine contains an adenovirus, a virus that can cause the common cold, which is rendered harmless; polysorbate and other ingredients.

NOTE: In-line links reference additional content of interest chosen by the WSJ news team.

This item is part of a Wall Street Journal live coverage event. The full stream can be found by searching P/WSJL (WSJ Live Coverage).

(END) Dow Jones Newswires

04-08-21 1350ET

Stocks mentioned in the article
ChangeLast1st jan.
BIONTECH SE -0.51% 121.52 Delayed Quote.49.83%
JOHNSON & JOHNSON 0.24% 161.64 Delayed Quote.2.46%
MODERNA, INC. -1.08% 139.4 Delayed Quote.34.89%
PFIZER, INC. 1.01% 36.97 Delayed Quote.-0.57%
All news about JOHNSON & JOHNSON
12:29pTHE LATEST : CDC head warns against surging shots to Michigan
12:19pEuropean Stocks Close in Red Ahead of Earnings Season Kickoff
10:58aPULMATRIX  : to Regain Full Rights to Narrow Spectrum Kinase Inhibitor Portfolio..
10:46aJOHNSON & JOHNSON  : Starts Delivering COVID-19 Vaccine to EU
10:07aJOHNSON & JOHNSON  : to Participate in the BofA Securities Virtual 2021 Healthca..
09:29aWALL STREET STOCK EXCHANGE : Confidence is high
08:00aSpain expects first batch of single-dose Janssen shot within 48 hours
07:39aPULMATRIX  : J&J Terminates License, Development, Commercialization Pact
01:28aFrance Lengthens Interval Between Two COVID-19 Jab Doses to Speed Up Vaccine ..
04/10ISS joins Glass Lewis in recommending vote against J&J CEO's pay package
More news
Financials (USD)
Sales 2021 92 667 M - -
Net income 2021 22 297 M - -
Net cash 2021 2 687 M - -
P/E ratio 2021 19,6x
Yield 2021 2,60%
Capitalization 425 B 425 B -
EV / Sales 2021 4,55x
EV / Sales 2022 4,29x
Nbr of Employees 134 500
Free-Float 83,5%
Duration : Period :
Johnson & Johnson Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 180,51 $
Last Close Price 161,25 $
Spread / Highest target 24,7%
Spread / Average Target 11,9%
Spread / Lowest Target -5,12%
EPS Revisions
Managers and Directors
Alex Gorsky Chairman & Chief Executive Officer
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Paulus Stoffels Chief Scientific Officer
James D. Swanson Global Chief Information Officer & Executive VP
Charles O. Prince Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON2.46%424 524
ROCHE HOLDING AG0.21%288 043
PFIZER, INC.-0.57%204 161
NOVARTIS AG-3.29%197 172
MERCK & CO., INC.-6.71%193 164
ABBVIE INC.0.36%189 789